Who are Celestial Therapeutics's investors?

Celestial Therapeutics's investors include StartX.

How much funding has Celestial Therapeutics raised?

Celestial Therapeutics has disclosed $2.2M raised across 2 rounds.

Where is Celestial Therapeutics headquartered?

Celestial Therapeutics is headquartered in Irvine, US.

Celestial Therapeutics

Irvine, US · Founded 2019 · Delaware corporation · 1 known investors

Find your way into Celestial Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Celestial Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Celestial Therapeutics is a biotech company whose team works across genetics, virology, bioengineering, pulmonary surfactant lipid and protein chemistry, innate immunity, infectious diseases, and pharmacology. The available page provides only background on the founders' and team's expertise, without detailing specific products.

Biotech

Founders & leadership

Leontis TeryazosCo-Founder, CFO, Corporate Secretary & Board Member

Ajay Gupta Co-Founder, President, Chairman & CEOHe has over 30 years of experience in pharmaceutical and biotech executive roles, including serving as Chairman & CEO of Osta Biotechnologies and Chief Operating Officer at BioSyntech, with expertise spanning drug discovery, medicinal chemistry, regulatory affairs, and GMP manufacturing across oncology, infectious diseases, and medical devices; he holds a Ph.D. in synthetic organic chemistry from the University of Waterloo.

ANNELISE E BARRONNamed on SEC filing

Board

George SiberBoard director

Investors · 1

StartXlisted by StartXStanford · $10K – $1M

How we know: StartX's portfolio page · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$2.2M disclosed across 2 rounds · 2020–2024

▶$850KraisedJul 2026 · 11 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

Ajay GuptaExecutive Officer, Director
George SiberDirector
Leontis TeryazosExecutive Officer, Director

Amount sold: $850K
Minimum investment: $20K
First sale: Sep 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

▶$1.3MraisedApr 2024 · 13 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

ANNELISE E BARRONDirector
AJAY GUPTAExecutive Officer, Director
LEONTIS TERYAZOSExecutive Officer, Director

Amount sold: $1.3M
Minimum investment: $20K
Proceeds to insiders: $150K
First sale: Mar 2020
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.

Cartesian Therapeutics (NASDAQ: RNAC)Cartesian Therapeutics is a clinical-stage biotechnology company developing mRNA-based cell therapies aimed at treating autoimmune diseases. It focuses on immunology and applies an mRNA platform to broaden the use of cell therapy for patients.

Nasdaq Private MarketNasdaq Private Market operates infrastructure for private-company securities, offering liquidity programs (tender offers, buybacks, auctions), a secondary marketplace for accredited investors to buy and sell pre-IPO shares and funds, market data and intelligence, patented settlement technology, and capital-raising solutions. It serves private companies, employee shareholders, institutional and individual investors, and banks/brokers.

Tempest TherapeuticsTempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications. Its pipeline includes a dual-target CD19/BCMA CAR structure and a CD7-targeted mRNA lipid nanoparticle CAR-T delivery platform, with lead candidate TPST-4003 planned for trials in myasthenia gravis and multiple sclerosis.

Century Therapeutics, Inc.Century Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer. The company aims to make cell therapies more effective, tolerable, accessible and affordable than existing treatments.

Companies working in the same space as Celestial Therapeutics.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2023	$290.1K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Celestial Therapeutics do?: Celestial Therapeutics is a biotech company whose team works across genetics, virology, bioengineering, pulmonary surfactant lipid and protein chemistry, innate immunity, infectious diseases, and pharmacology. The available page provides only background on the founders' and team's expertise, without detailing specific products.
Who are Celestial Therapeutics's investors?: Celestial Therapeutics's investors include StartX.
How much funding has Celestial Therapeutics raised?: Celestial Therapeutics has disclosed $2.2M raised across 2 rounds.
Where is Celestial Therapeutics headquartered?: Celestial Therapeutics is headquartered in Irvine, US.